https://www.onltherapeutics.com/2023/04/12/onl-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-first-in-class-fas-inhibitor-in-patients-with-macula-off-rhegmatogenous-retinal-detachment/
Bernadette Ballard-Reid